Phase II Multicenter 3-cohort Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received 1 or 2 Prior Lines of Systemic Therapy for Advanced/Metastatic Disease
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Capmatinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Jul 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Jul 2018 Planned initiation date changed from 30 Nov 2017 to 31 Jul 2018.
- 09 Aug 2017 New trial record